EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study

Vandana Dhiman, Sanjay Kumar Bhadada, Poonam Kanta, Gurjeet Kaur, Swati Bhat, Amanjit Bal, Naresh Sachdeva, Anil Bhansali, Devinder Kumar Dhawan, Ravi Pratap Barnwal, Gurpal Singh, Sudhaker Dhanwada Rao

Indian Journal of Pharmacology · 2025

DOI: 10.4103/ijp.ijp_582_23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Pharmacology, 2025. Verfasst von Vandana Dhiman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India. Hauptthemen laut MEDLINE: Osteoblasts, Parathyroid Hormone, Diphosphonates, Imidazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0). Gefördert von: NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND Bone is an endocrine organ that despite being inert in appearance constantly undergoes remodeling, in which wear and tear of bone cells occur. With more than two decades of clinical experience, the molecular mechanisms of anti-fracture drugs are not completely understood because they inhibit osteoclastic activity and differentiate the osteoblast cells. Recent studies suggest fundamentally different mechanisms of action for key anti-fracture drugs, bisphosphonates, and recombinant human parathyroid hormone (rhPTH) at the tissue level; however, their molecular basis of action has not been explored completely. Here, we showed the effect of varying concentrations of zoledronic acid (ZOL) and rhPTH on human osteogenic sarcoma cells (U2OS cells). MATERIALS AND METHODS Cellular viability, mineralization, and osteogenic gene expressions were assessed to elucidate the effects of these two prototypic drugs with diametrically different mechanisms of action. RESULTS Cellular viability was not affected either by ZOL or rhPTH alone or in tandem treatments. Osteoblastic activity increased significantly with rhPTH followed by ZOL. Further, alkaline phosphatase activity increased significantly with tandem treatment of rhPTH followed by ZOL both at the mRNA and protein levels. Moreover, osteoblastic genes (COL1A1 and osteocalcin) were significantly modulated by sequential treatment with rhPTH followed by ZOL. CONCLUSIONS We conclude that rhPTH (5 μg) treatment followed by ZOL (1 μM) showed the best anabolic or bone-forming effect. Our results warrant further research in assessing similar combinations of anti-fracture drugs, which augment osteogenesis to maximize their anabolic effects in preventing osteoporosis in susceptible individuals.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OsteoblastsParathyroid HormoneDiphosphonatesImidazolesBone Density Conservation AgentsZoledronic AcidHumansRecombinant ProteinsCell SurvivalCell Line, TumorGene ExpressionAlkaline PhosphataseOsteocalcinCollagen Type ICollagen Type I, alpha 1 ChainOsteogenesis

Stichwörter der Autor:innen

Bisphosphonateboneosteocalcinosteoporosiszoledronic acid

Substanzen

Zoledronic AcidRecombinant ProteinsParathyroid HormoneDiphosphonatesImidazolesBone Density Conservation AgentsAlkaline PhosphataseOsteocalcinCollagen Type ICollagen Type I, alpha 1 Chain

Autor:innen und Institutionen

  • Department of Endocrinology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Biochemistry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Histopathology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
  • Department of Biophysics, Panjab University, Chandigarh, India.
  • University Institute of Pharmaceutical Sciences Panjab University, Chandigarh, India.
  • Bone and Mineral Research Laboratory, Henry Ford Health System, Detroit, MI, USA.

Förderung

  • NIAMS NIH HHS

Zitieren

APA

Dhiman, V., Bhadada, S. K., Kanta, P., Kaur, G., Bhat, S., Bal, A., Sachdeva, N., Bhansali, A., Dhawan, D. K., Barnwal, R. P., Singh, G., & Rao, S. D. (2025). Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study. Indian Journal of Pharmacology. https://doi.org/10.4103/ijp.ijp_582_23

Vancouver

Dhiman V, Bhadada SK, Kanta P, Kaur G, Bhat S, Bal A, et al. Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study. Indian Journal of Pharmacology. 2025. doi:10.4103/ijp.ijp_582_23

BibTeX
@article{Dhiman2025,
  author = {Dhiman, Vandana and Bhadada, Sanjay Kumar and Kanta, Poonam and Kaur, Gurjeet and Bhat, Swati and Bal, Amanjit and Sachdeva, Naresh and Bhansali, Anil and Dhawan, Devinder Kumar and Barnwal, Ravi Pratap and Singh, Gurpal and Rao, Sudhaker Dhanwada},
  title = {Effect of recombinant human parathyroid hormone and zoledronic acid on osteoblast gene expression using multifaceted approach: An in vitro study},
  journal = {Indian Journal of Pharmacology},
  year = {2025},
  doi = {10.4103/ijp.ijp_582_23}
}
Kostenlos starten →